The molecular structure of OBI-858 is a special toxin protein with a molecular weight of 760 kDa, which is produced by the botulinum toxin type A bacteria during its fermentation. Results of Phase 1 clinical trial showed the product was safe and well-tolerated.
OBIGEN Pharma
The first biotechnology startup company in Taiwan that engages in the research, development, production and manufacturing of botulinum toxin.
Announcements
OBIGEN Pharma
Being the first startup company in Taiwan that engages in the research, development, production and manufacturing of botulinum toxin, OBIGEN Pharma has the vision of utilizing its core competencies, abiding by the highest quality and safety standards, actively and diligently developing and producing stable quality products, and contributing more innovation and vitality into the entire medical aesthetic and therapeutic industry.
Core Values
- Abide by the highest quality and safety standards.
- Built an API plant that meets the standards of the International Organization for the Inspection of Pharmaceutical Products (PIC/s GMP).
The Vision of OBIGEN Pharma
- Develop and produce world class products.
- Provide consumers with a better choice for the pursuit of true beauty and quality of life.
Management Team
- The management team is comprised of professionals with biopharmaceutical and chemical background.
Introduction of Taiwan Toxin OBI-858
The molecular structure of OBI-858 is a special toxin protein with a molecular weight of 760 kDa, which is produced by the botulinum toxin type A bacteria during its fermentation. Originated from the same bacterial species as those on the market. Such bacteria are regulated as biological warfare internationally.
Contact Information
11F.-6 & 11F.-7, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302041, Taiwan (R.O.C.)
+886-2-2786-1217